A carregar...
Pharmacokinetics of Gepotidacin in Renal Impairment
Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. In this phase 1, nonrandomized, open‐label, parallel‐group, multicenter, multipart study, the pharmacokinetics, safety, and tolerability of a single intravenous (IV) dose of gepotidacin 750 mg over 2 hours were evaluated...
Na minha lista:
| Publicado no: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384084/ https://ncbi.nlm.nih.gov/pubmed/32429000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.807 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|